Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Terns Pharmaceuticals (TERN) EBITDA (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of EBITDA readings, the most recent being -$23.2 million for Q4 2025.

  • Quarterly EBITDA fell 134.48% to -$23.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$95.4 million through Dec 2025, down 25481.91% year-over-year, with the annual reading at -$20.1 million for FY2025, 80.29% up from the prior year.
  • EBITDA hit -$23.2 million in Q4 2025 for Terns Pharmaceuticals, up from -$24.5 million in the prior quarter.
  • Across five years, EBITDA topped out at $67.3 million in Q4 2024 and bottomed at -$29.8 million in Q3 2023.
  • Average EBITDA over 5 years is -$14.9 million, with a median of -$19.6 million recorded in 2023.
  • The largest annual shift saw EBITDA soared 420.7% in 2024 before it plummeted 134.48% in 2025.
  • Terns Pharmaceuticals' EBITDA stood at -$13.9 million in 2021, then fell by 21.26% to -$16.8 million in 2022, then fell by 24.61% to -$21.0 million in 2023, then soared by 420.7% to $67.3 million in 2024, then plummeted by 134.48% to -$23.2 million in 2025.
  • Per Business Quant, the three most recent readings for TERN's EBITDA are -$23.2 million (Q4 2025), -$24.5 million (Q3 2025), and -$24.2 million (Q2 2025).